bpc-157 oral administration bioavailability (10mg vial) AOD 9604 Peptide Therapy: Red Blood Cell Production Syringe Size:31G

bpc-157 oral administration bioavailability (10mg vial) AOD 9604 Peptide Therapy: Red Blood Cell Production Syringe Size:31G

AOD 9604 Peptide Therapy: The “Fat-Burning”...

You will then meet with one of the team members for your Vitamin Lounge Initial Visit (30 min) or Naturopathic Initial Visit (60 min+) (for the most comprehensive approach)

Red Blood Cell Production

Syringe Size:31G

Eligibility (key inclusion criteria): Age 18–45 years Acute posterior thigh pain consistent with hamstring strain, onset within 72 hours of screening MRI-confirmed grade II hamstring strain (biceps femoris, semitendinosus, or semimembranosus) with measurable lesion Physical activity ≥3 sessions/week or organized recreational sport participation Willingness to complete all study visits and follow the standardized rehabilitation protocol Key exclusion criteria: Grade III hamstring tear, avulsion, or injury requiring surgery Prior hamstring strain on the same limb within 6 months Concomitant use of systemic corticosteroids, anabolic agents, platelet-rich plasma, stem-cell products, or investigational peptides/growth factors within 30 days Current participation in anti-doping testing programs (WADA/USADA-aligned) unless explicitly approved by the relevant authority Primary Endpoints The trial uses two co-primary endpoints: Time to return to unrestricted sport participation (days): Defined as clinician clearance combined with completion of a standardized functional performance battery without pain-limited stopping